Extinguishing the rewarding value of smoke cues: pharmacological and behavioral treatments
- PMID:15203786
- DOI: 10.1080/14622200410001696501
Extinguishing the rewarding value of smoke cues: pharmacological and behavioral treatments
Abstract
The present study examined several pharmacological and behavioral treatments designed to promote extinction of the responses to rewarding cigarette smoke cues. Pharmacological treatments comprised nicotine skin patches (21 mg/24 hr) and the nicotinic acetylcholine receptor antagonist mecamylamine (10 mg/day), administered separately or in combination. Behavioral manipulations included switching to denicotinized cigarettes, to cigarettes having different menthol flavor, or to ventilated-filter (low tar and nicotine) cigarettes. Smokers were assigned to the various treatments for 2 weeks before they quit smoking. During weekly test sessions, subjects rated the rewarding effects of their usual brands of cigarettes or cigarettes with different menthol content (mentholated vs. nonmentholated). Over the 2-week treatment period, all pharmacological treatments reduced ratings of reward for the usual-brand test cigarettes. Switching to smoking denicotinized cigarettes for 2 weeks similarly decreased rewarding effects of the usual-brand test cigarettes. Subjects also strongly preferred cigarettes with the same menthol content to which they were accustomed. However, manipulating the menthol content of the cigarettes smoked during the 2 weeks of treatment had different effects, depending on whether smokers habitually smoked mentholated or nonmentholated cigarettes. For menthol smokers, removal of the menthol cue hampered extinction of reward ratings for the usual-brand (mentholated) test cigarette. For nonmenthol smokers, addition of the menthol cue did not affect the progress of extinction of nonmenthol smoke cues. These findings demonstrate the importance of sensory cues in determining subjective reward and show that the reward value of these cues can be altered by removal of nicotine from tobacco or by pharmacological manipulations that interfere with the reinforcing effects of nicotine.
Similar articles
- Precessation treatment with nicotine skin patch facilitates smoking cessation.Rose JE, Behm FM, Westman EC, Kukovich P.Rose JE, et al.Nicotine Tob Res. 2006 Feb;8(1):89-101. doi: 10.1080/14622200500431866.Nicotine Tob Res. 2006.PMID:16497603Clinical Trial.
- Treating smokers before the quit date: can nicotine patches and denicotinized cigarettes reduce cravings?Rezaishiraz H, Hyland A, Mahoney MC, O'Connor RJ, Cummings KM.Rezaishiraz H, et al.Nicotine Tob Res. 2007 Nov;9(11):1139-46. doi: 10.1080/14622200701684172.Nicotine Tob Res. 2007.PMID:17978987Clinical Trial.
- Platelet monoamine oxidase, smoking cessation, and tobacco withdrawal symptoms.Rose JE, Behm FM, Ramsey C, Ritchie JC Jr.Rose JE, et al.Nicotine Tob Res. 2001 Nov;3(4):383-90. doi: 10.1080/14622200110087277.Nicotine Tob Res. 2001.PMID:11694206Clinical Trial.
- Role of nicotine pharmacokinetics in nicotine addiction and nicotine replacement therapy: a review.Le Houezec J.Le Houezec J.Int J Tuberc Lung Dis. 2003 Sep;7(9):811-9.Int J Tuberc Lung Dis. 2003.PMID:12971663Review.
- The relevance and treatment of cue-induced cravings in tobacco dependence.Ferguson SG, Shiffman S.Ferguson SG, et al.J Subst Abuse Treat. 2009 Apr;36(3):235-43. doi: 10.1016/j.jsat.2008.06.005. Epub 2008 Aug 20.J Subst Abuse Treat. 2009.PMID:18715743Review.
Cited by
- The effects of extended pre-quit varenicline treatment on smoking behavior and short-term abstinence: a randomized clinical trial.Hawk LW Jr, Ashare RL, Lohnes SF, Schlienz NJ, Rhodes JD, Tiffany ST, Gass JC, Cummings KM, Mahoney MC.Hawk LW Jr, et al.Clin Pharmacol Ther. 2012 Feb;91(2):172-80. doi: 10.1038/clpt.2011.317. Epub 2011 Nov 30.Clin Pharmacol Ther. 2012.PMID:22130118Free PMC article.Clinical Trial.
- Effects of Framing Nicotine Reduction in Cigarettes on Anticipated Tobacco Product Use Intentions and Risk Perceptions Among US Adult Smokers.Popova L, Owusu D, Nyman AL, Weaver SR, Yang B, Huang J, Ashley DL.Popova L, et al.Nicotine Tob Res. 2019 Dec 23;21(Suppl 1):S108-S116. doi: 10.1093/ntr/ntz146.Nicotine Tob Res. 2019.PMID:31867652Free PMC article.
- Repeated nicotine exposure during adolescence alters reward-related learning in male and female rats.Quick SL, Olausson P, Addy NA, Taylor JR.Quick SL, et al.Behav Brain Res. 2014 Mar 15;261:171-6. doi: 10.1016/j.bbr.2013.12.001. Epub 2013 Dec 12.Behav Brain Res. 2014.PMID:24333376Free PMC article.Clinical Trial.
- Menthol tobacco use is correlated with mental health symptoms in a national sample of young adults: implications for future health risks and policy recommendations.Cohn AM, Johnson AL, Hair E, Rath JM, Villanti AC.Cohn AM, et al.Tob Induc Dis. 2016 Jan 8;14:1. doi: 10.1186/s12971-015-0066-3. eCollection 2016.Tob Induc Dis. 2016.PMID:26752983Free PMC article.
- Internal tobacco industry research on olfactory and trigeminal nerve response to nicotine and other smoke components.Megerdichian CL, Rees VW, Wayne GF, Connolly GN.Megerdichian CL, et al.Nicotine Tob Res. 2007 Nov;9(11):1119-29. doi: 10.1080/14622200701648458.Nicotine Tob Res. 2007.PMID:17978985Free PMC article.Review.
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Medical